Drug intelligence / Profile preview

PTH recombinant plasmid

Development stage: Unknown
Lead developer: Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
Modality: Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
Administration: Intramuscular

Overview

PTH recombinant plasmid is a gene therapy drug designed to treat hypoparathyroidism by delivering the gene for parathyroid hormone (PTH). Once delivered, the plasmid enables cells to produce biologically active PTH, which is crucial for regulating calcium and phosphate homeostasis. This approach aims to restore normal PTH levels in patients who are deficient in the hormone.

Other names: recombinant parathyroid hormone plasmidrecombinant human parathyroid hormone (1-84) plasmid injectionhPTH plasmidhPTH(1-84) plasmid

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on PTH recombinant plasmid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTH recombinant plasmid.

Explore the full profile